New Hungary Pharma Report 2020 Out Now
In line with its status as one of Europe’s most dynamic economies, Hungary is aiming to boost both its life sciences industry and the level of healthcare it provides to…
Founded in 1908, LEO Pharma is an independent, research-based pharmaceutical company.
LEO Pharma develops, manufactures and markets pharmaceutical drugs to dermatologic and thrombotic patients in more than 100 countries globally. To realise our vision of becoming the preferred dermatology care partner improving people’s lives around the world, we are expanding into new regions and markets, reaching more patients and societies with drugs and therapies that address unmet medical needs.
LEO Pharma has its own sales forces in 61 countries and employs around 5,000 employees worldwide and generates approximately USD 1.2 billion in annual turnover. The company is headquartered in Denmark and is wholly owned by the LEO Foundation.
2015 was the year LEO Pharma embarked on our ‘Helping SARAH – LEO towards 2020’ journey – a new strategy which was launched in December 2014. With the ambitious aspiration to help more than 100 million people in 2020, LEO Pharma has committed itself to looking at new and innovative solutions and keeping engaging in partnerships to reach its goal. LEO Pharma wants to offer solutions in all aspects of life for people living with skin diseases, to assist them in taking control of their condition and improve their quality of life. We have set out on a mission to help people achieve healthy skin; in addition to our products, we offer patients a growing list of solutions and services. As part of our 2020 strategy, we have established LEO Innovation Lab, a separate business unit operating independently outside our traditional business. LEO Innovation Lab works to improve the well-being of people living with psoriasis by developing digital solutions and services. Generic competition is today a market condition when running a pharmaceutical business with strong products and solutions, and 2015 was no exception. This year we upheld our patents for Daivobet® Ointment in court rulings in the UK and Canada. The result for 2015 is considered satisfactory
Contact
LEO Pharma A/S Hungarian Commercial Representative Office
Regus Obuda Gate
Arpad fejedelem utja 26-28., 5th floor
1023 Budapest
Hungary
Tel. (+36) 1 888 0525
In line with its status as one of Europe’s most dynamic economies, Hungary is aiming to boost both its life sciences industry and the level of healthcare it provides to…
Hungary’s longstanding tradition of pharmacology is a major point of pride for the country’s scientists and researchers who today have hopes to elevate the country’s research environment to a region-leading…
According to Peter Holchacker, director general of Hungary’s Association of Innovative Pharmaceutical Manufacturers (AIPM), “clinical trials initiated by multinational companies, represent, on average, an investment of approximately EUR 300 million…
Established in 1997, Medi-Radiopharma is a Hungarian privately held company operating in the field of nuclear medicine, a specialized area of radiology that uses very small amounts of radioactive materials,…
As general manager of the Hungarian affiliate of Swiss firm IBSA, Anna Wienner has proven herself to be a motivated pharma leader with particular expertise in reshaping and building organizations.…
Krisztina Kárpát, MD of Bayer Hungary, elaborates on the successful development of the affiliate in recent years, making progress in all three business units of pharma, consumer health, and crop…
Judit Bidlo, deputy director general of price support at the Hungarian National Health Insurance (NEAK), shares her insights on the healthcare system’s developments over the last three years, the rationale…
Among the efforts of Hungarian stakeholders to determine more efficient pricing and reimbursement structures, there is a common ambition to explore what is considered by many to be the next…
In 2016, Hungary transitioned from a second-tier member to a full member of the EU. As Judit Bidló, deputy director general of pricing and reimbursement for Hungary’s National Institute of…
Tamás Demeter, Country Manager for AOP Orphan shares his insights on the footprint of the company in Hungary, the areas of therapeutic need that AOP caters to, the performance of…
Katinka Zinnemers, managing director of Abacus Medicine, highlights the company’s mission to increase access to medicines for all patients and its commitment to building trust with authorities as it enters…
Csaba Kis, CEO of Qualiskills, shares his insights on the packaging capabilities of the company, its sustainable competitive advantage, the impact of the European serialization guidelines, and the company’s strategic…
See our Cookie Privacy Policy Here
